Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares MSCI India ETF (INDA) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
iShares MSCI India ETFTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares MSCI India ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $353.31 (market cap $9.43B), while iShares MSCI India ETF trades at $49.94. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.

BIOINDA
Market Cap
$9.43B
Sector
HealthBroad Market / Factor
52-Week High
$356.25$55.29
52-Week Low
$241.71$45.42
Enterprise Value
$9.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.

BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.

iShares MSCI India ETF

INDA trades at $50.04, down 0.2% with a bullish technical signal from moving averages. The ETF reflects India's economic growth at 7.8% (CNBC, 2026-06-05) but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX indicates strong trend strength.

Outlook remains cautiously optimistic given India's strong economic fundamentals, though near-term risks include geopolitical tensions, monsoon uncertainties, and foreign capital rotation away from emerging markets. The ETF offers exposure to the world's fastest-growing large economy but requires monitoring of external pressures.

Returns comparison

Trailing returns across standard periods

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About iShares MSCI India ETF

INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.

Read more on INDA